EN DE
Watch Dimerix Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Dimerix Ltd (DXB) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Dimerix Ltd stock A$0.15, price A$0.22, that is 30.2% below the price, quality 29 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU000000DXB7

DL Dimerix Ltd logo Thin data Nov 10, 2026

Dimerix Ltd

DXB · AU
Expensive, weak quality

Our calculation puts a fair price 30% below what the stock costs today.

Negative equity (buybacks among others)
Moderate moat 49/100 · thin data
Revenue last quarter 20% below a year ago.
Fair value A$0.1501 · Overvalued
Quality 29/100
Weak Growth (revenue 5y −0.4 %/yr in AUD)
Negative free cash flow
Trails peers (1/6)
Thin data
Estimate
Watch Dimerix Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.7550 A$0.0570 Fair Value A$0.1501 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range A$0.0570 – A$0.7550 · fair‑value band A$0.1126 – A$0.1876 · the A$0.2150 price screens above the A$0.1501 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Dimerix in your weekly email

Every Wednesday you see whether Dimerix is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.

Show moreShow less

It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.

Stock analysis

Dimerix Ltd (DXB) currently trades at A$0.2150, while our estimate is A$0.1501, 30% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: A$0.1126 (bear) to A$0.1876 (bull), the price of A$0.2150 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Dimerix Ltd reported revenue of A$4.4M in FY2026 versus A$6.5M in FY2022, a compound −9.4%/yr. Reported net income was −A$29.8M in FY2026.

Key figures

Market cap A$129M (≈ $88.8M) Micro · P/S ratio 20.3 · EPS (TTM) A$−0.0500 · Return on equity −595% · Return on assets (EBIT) −74.8% (5-year average) · Operating margin −318% · Revenue (TTM) A$6.4M · Revenue growth (YoY) −20.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).

What moves the price

The share trades about 66% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −30%, DXB screens richer than that median.

Fair Value

Bear A$0.1126 Fair Value A$0.1501 Bull A$0.1876
Price A$0.2150 · Downside -30.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 28
Do the profits arrive as real cash?
Financial strength 31
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 4
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 2/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+246.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
Start year 2021 (pandemic). Over 10 years: +21.7% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−246.1% (2021) → −854.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

DXB screens overvalued: fair value 30% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Dimerix Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −30.2% · Below median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −50.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −20.0% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 20.32× · Priciest 25%
PEG 0.72× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs DXB
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs DXB
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs DXB
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs DXB
argenx SE ARGX $971.55 $908.40 −7% vs DXB
CSL Limited CSL A$201.68 A$181.40 −10% vs DXB
Moderna, Inc MRNA $250.83 $158.70 −37% vs DXB
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs DXB
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs DXB
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs DXB

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Dimerix Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Dimerix Ltd Fair Value". https://www.fairvalue-calculator.com/stock/DXB

Frequently asked questions

Is Dimerix Ltd (DXB) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is A$0.1501 versus a price of A$0.2150, about 30% lower (overvalued).
What is the fair value of DXB?
Our estimate for Dimerix Ltd is A$0.1501 (as of Nov 10, 2026), built from audited fundamentals. The current price: A$0.2150.
What is the quality score of DXB?
Dimerix Ltd has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dimerix Ltd (DXB)?
Our calculated price target is the estimate of A$0.1501 (as of Nov 10, 2026). Cautious scenario A$0.1126, optimistic scenario A$0.1876. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Dimerix Ltd stock forecast for 2026?
Our estimate puts fair value at A$0.1501, about 30% lower versus a price of A$0.2150 (overvalued). Cautious scenario A$0.1126, optimistic scenario A$0.1876. The calculation is refreshed regularly with new filings.
What is the revenue of Dimerix Ltd (DXB)?
Dimerix Ltd reported trailing-twelve-month revenue of about A$6.4M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Dimerix Ltd (DXB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dimerix Ltd it is A$0.1501 per share (as of Nov 10, 2026), against a price of A$0.2150.
Is Dimerix Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, DXB trades above its calculated fair value: price A$0.2150, fair value A$0.1501, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DXB?
No. The price is what the market pays today (A$0.2150); the fair value is what the company's own numbers justify (A$0.1501). For Dimerix Ltd the two are A$0.0649 per share apart. That gap is exactly why we show both numbers side by side.
How much is Dimerix Ltd worth?
The market values Dimerix Ltd at about A$129M (market capitalisation, as of Nov 10, 2026). Per share that is A$0.2150; our models calculate a fair value of A$0.1501 per share.
What do the bullish and bearish scenarios say about DXB?
Our models span a range for Dimerix Ltd: cautious scenario A$0.1126, base A$0.1501, optimistic A$0.1876 per share (as of Nov 10, 2026, price A$0.2150). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of DXB?
The PEG ratio of Dimerix Ltd is 0.72 (P/E divided by earnings growth, as of Nov 10, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Dimerix Ltd (DXB)?
Balance-sheet figures for Dimerix Ltd (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is DXB from its 52-week high?
Dimerix Ltd trades at A$0.2150, about 66% below its 52-week high of A$0.6250 and 30% above the low of A$0.1650 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.1501 is for.
Which stocks are comparable to Dimerix Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dimerix Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price A$0.2150, calculated fair value A$0.1501 (−30%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Dimerix Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dimerix Ltd (DXB)?
The closing price on Nov 11, 2026 was A$0.2150. Our estimate is A$0.1501, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dimerix Ltd right now?
The price sits above even our optimistic bull case (A$0.1876). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Dimerix Ltd

How large is the market capitalisation of Dimerix Ltd (DXB)?
The market capitalisation of Dimerix Ltd is A$129M (≈ $88.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dimerix Ltd (DXB)?
The price-to-sales ratio of Dimerix Ltd is 20.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dimerix Ltd (DXB)?
Earnings per share at Dimerix Ltd are A$−0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Dimerix Ltd (DXB)?
The return on equity (ROE) of Dimerix Ltd is −595% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dimerix Ltd (DXB)?
On an EBIT basis the return on assets of Dimerix Ltd is −74.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dimerix Ltd (DXB)?
The operating margin of Dimerix Ltd is −318% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dimerix Ltd (DXB)?
Revenue at Dimerix Ltd is growing −20.0% versus a year earlier (3y avg +391%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Dimerix Ltd (DXB) generate?
The free cash flow of Dimerix Ltd is −A$51.8M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Dimerix Ltd (DXB) hold?
Dimerix Ltd holds more cash than debt, A$15.9M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Dimerix Ltd in the live analysis

One click puts Dimerix Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.